Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for Breast Cancer Drug Combo
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading pharmaceutical company in China, has announced that it...
Shineco Partners with Tuling Vision to Develop Intelligent Healthcare Solutions
Shineco Inc. (NSDQ: SISI), a U.S.-based company, has signed a partnership deal with China-headquartered Tuling...
Wuxi’s Binhu District Partners with Fresenius Kabi to Boost Healthcare Services
The Binhu District People’s Government of Wuxi, Jiangsu province, China, has entered into a partnership...
Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Phase II Trial in Pancreatic Cancer
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...
Walvax Biotechnology Halts COVID-19 Vaccine Clinical Trials Citing Low Benefits
Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the...
Sichuan Kelun-Biotech Receives NMPA Clearance for SKB518 Clinical Trial in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...
Sinovac Partners with Brazil’s Fiocruz to Boost Vaccine Research and Development
Fiocruz, a renowned health research center based in Brazil, has announced a collaboration agreement with...
BioNTech and MediLink’s HER3 ADC BNT326 Faces Partial Clinical Hold in the US
BioNTech SE (NASDAQ: BNTX), a German biotechnology company, and its Chinese co-development partner MediLink Therapeutics...
Takeda’s Soticlestat Misses Primary Endpoints in Phase III Epilepsy Trials
Takeda Pharmaceutical Co., Ltd (TYO: 4502; NYSE: TAK), a leading Japanese pharmaceutical company, has announced...
Amgen’s Blincyto Secures New Indication Approval for B-ALL Consolidation Treatment in the US
Amgen (NASDAQ: AMGN) has announced that its bispecific T-cell engager (BiTE) Blincyto (blinatumomab) has received...
MSD’s Keytruda Secures FDA Approval for Advanced or Recurrent Endometrial Carcinoma
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...
AbbVie Warns Shareholders Against Tutanota’s Unsolicited Mini-Tender Offer
Private investment firm Tutanota has launched an unsolicited mini-tender offer to acquire up to 250,000...
FDA Approves Broadened Use of BMS’ Next-Gen TKI Augtyro for Advanced Solid Tumors
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...
CATUG Biotechnology Secures Nearly RMB 100 Million in Latest Financing Round to Expand Globally
CATUG Biotechnology, a cutting-edge company in the nucleic acid and gene therapy sector, has announced...
Neusoft IntelliRay Secures Over RMB 100 Million in Series C Funding Round
Neusoft IntelliRay Technology Co., Ltd, a medical technology company based in Shenyang, has successfully closed...
Takeda Secures Global Rights to Ascentage Pharma’s Olverembatinib Outside of China and Select Territories
Takeda Pharmaceuticals, a leading biopharmaceutical company based in Japan (TYO: 4502), has entered into an...
CARsgen Therapeutics’ Saikaize and CT071 Show Strong Results in EHA Clinical Trials
CARsgen Therapeutics, a biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 2171), has...
RemeGen’s Disitamab Vedotin Shows Positive Results in Phase III Trial for HER2 Positive Breast Cancer
RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced positive results from...
AbbVie Strikes Deal with FutureGen for Global Rights to Next-Gen TL1A Antibody FG-M701
AbbVie (NYSE: ABBV), a biopharmaceutical giant based in the US, has announced a licensing agreement...
BeiGene to Terminate Partnership with NewBridge Pharmaceuticals for MENA Region
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company based in China, has...